Skip to contentH
Hepion Pharmaceuticals, Inc.
H
HEPAHepion Pharmaceuticals, Inc. Q3 2020 · 10-Q
Revenue$0.00$0.00no prior Q3 2019 on file Net Income-$6.23M-$6.23MN/M vs Q3 2019 EPS Diluted-$0.69-$0.69N/M vs Q3 2019 Operating Income-$6,230,994N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,850,479N/M ended Sep 30, 2020 · filed Nov 16, 2020 · 47 d after period end